OncoMatch/Clinical Trials/NCT06698484
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
Is NCT06698484 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies CAR-T cells for relapsed/refractory b- cell non-hodgkin lymphoma.
Treatment: CAR-T cells — A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for hematopoietic stem cell transplantation (HCT)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: second-line treatment — refractory
refractory to second-line treatment
Must have received: first-line treatment — relapsed
relapsed after first-line treatment with no available curative options such as autologous or allogeneic haematopoietic stem cell transplantation (HSCT)
Cannot have received: autologous or allogeneic stem cell transplant
Exception: allowed if >12 weeks before enrolment
Receiving autologous or allogeneic stem cell transplant within 12 weeks of enrolment
Lab requirements
Blood counts
absolute neutrophil count ≥ 1500/μl, haemoglobin level ≥ 7 g/dl, platelets ≥ 50000/μl
Kidney function
creatinine clearance >40 ml/min
Liver function
serum alanine transaminase (alt) < 5 times the normal value, serum bilirubin < 3 times the normal value
Cardiac function
left ventricular ejection fraction > 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06698484 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous or allogeneic stem cell transplant disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 13 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages